Nipun Lakshitha De Silva,Nikoleta Papanikolaou,Mathis Grossmann et al.
Nipun Lakshitha De Silva et al.
Organic male hypogonadism due to irreversible hypothalamic-pituitary-testicular (HPT) pathology is easily diagnosed and treated with testosterone-replacement therapy. However, controversy surrounds the global practice of prescribing testost...
The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology
Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation [0.03%]
英国国家医疗服务体系2型糖尿病缓解计划的初步结果——现实条件下实施情况的前瞻性评价
Jonathan Valabhji,Tessa Gorton,Emma Barron et al.
Jonathan Valabhji et al.
Background: Randomised controlled trials have shown that total diet replacement (TDR) can lead to remission of type 2 diabetes. In 2019, the English National Health Service (NHS) committed to establishing a TDR-based inte...
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes [0.03%]
胰岛素抵抗在2型糖尿病管理中的忽视及应对措施
Muhammad Abdul-Ghani,Pietro Maffei,Ralph Anthony DeFronzo
Muhammad Abdul-Ghani
Glucagon-like peptide-1 (GLP-1) receptor agonists have gained widespread use in the treatment of individuals with type 2 diabetes because of their potent weight loss promoting effect, ability to augment β-cell function, and cardiovascular ...
Xavier Rossello,Francisca Caimari
Xavier Rossello
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study [0.03%]
西班牙杂合子家族性高胆固醇血症患者动脉粥样硬化心血管疾病长期性别差异：一项来自SAFEHEART（全国多中心前瞻性队列研究）的研究
Leopoldo Pérez de Isla,Antonio J Vallejo-Vaz,Gerald F Watts et al.
Leopoldo Pérez de Isla et al.
Background: Sex differences in atherosclerotic cardiovascular disease (ASCVD) in familial hypercholesterolaemia have been reported but are not fully established. We aimed to assess sex differences in the risk of ASCVD and...
Correction to Lancet Diabetes Endocrinol 2024; published online July 19. https://doi.org/10.1016/S2213-8587(24)00157-8 [0.03%]
柳叶刀糖尿病内分泌学2024年在线发表的更正：https://doi.org/10.1016/S2213-8587(24)00157-8
Published Erratum
The lancet. Diabetes & endocrinology. 2024 Sep;12(9):e18. DOI:10.1016/S2213-8587(24)00244-4 2024
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial [0.03%]
一周一次司美格鲁肽2.4毫克治疗具有糖尿病前期的肥胖症患者的疗效和安全性（STEP 10）：一项随机、双盲、安慰剂对照、多中心III期临床试验
Barbara M McGowan,Jens M Bruun,Matt Capehorn et al.
Barbara M McGowan et al.
Background: There are currently limited data regarding the effect of semaglutide 2·4 mg in individuals with obesity and prediabetes in clinical trials. We aimed to assess the efficacy and safety of semaglutide 2·4 mg fo...